Author Archives: admin


Chalice Brands Ltd. Announces Flagship Superstore and Relationship with Aventine Property Group

PORTLAND, Ore., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Chalice Brands Ltd. (CSE:CHAL) (OTCQB:CHALF) (“Chalice” or the “Company”), a premier consumer-driven cannabis company specializing in retail, production, processing, wholesale, and distribution, is pleased to announce it has successfully completed an agreement (the “Agreement”) to lease a retail property located in Portland, Oregon from Aventine Property Group, Inc. (“Aventine”).

See more here:
Chalice Brands Ltd. Announces Flagship Superstore and Relationship with Aventine Property Group

iOnctura Presents Positive Clinical Data At ESMO-IO Supporting Advancement of IOA-289, a Novel Autotaxin Inhibitor, Into Phase Ib Pancreatic Cancer…

GENEVA, Switzerland, Dec. 09, 2021 (GLOBE NEWSWIRE) -- iOnctura SA, a clinical stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface, is presenting clinical data confirming the mode of action of its autotaxin inhibitor IOA-289 and showing preclinical evidence of the role of autotaxin inhibition in breaking down tumor resistance mechanisms. IOA-289 will be the first autotaxin inhibitor to be clinically investigated in oncology. The data will be presented as a poster at the European Society of Medical Oncology’s Immuno-Oncology Congress (ESMO-IO) taking place on December 8–11, 2021 as a virtual meeting.

Visit link:
iOnctura Presents Positive Clinical Data At ESMO-IO Supporting Advancement of IOA-289, a Novel Autotaxin Inhibitor, Into Phase Ib Pancreatic Cancer...

Syrian refugee is thriving five years after last-gasp gene therapy – STAT – STAT

In the summer of 2015, a 7-year-old named Hassan was admitted to the burn unit of the Ruhr University Childrens Hospital in Bochum, Germany, with red, oozing wounds from head to toe.

It wasnt a fire that took his skin. It was a bacterial infection, resulting from an incurable genetic disorder. Called junctional epidermolysis bullosa, the condition deprives the skin of a protein needed to hold its layers together and leads to large, painful lesions. For kids, its often fatal. And indeed, Hassans doctors told his parents, Syrian refugees who had fled to Germany, the young boy was dying.

The doctors tried one last thing to save him. They cut out a tiny, unblistered patch of skin from the childs groin and sent it to the laboratory of Michele de Luca, an Italian stem cell expert who heads the Center for Regenerative Medicine at the University of Modena and Reggio Emilia. De Lucas team used a viral vector to ferry into Hassans skin cells a functional version of the gene LAMB3, which codes for laminin, the protein that anchors the surface of the skin to the layers below.

advertisement

Then the scientists grew the modified cells into sheets big enough for Ruhr University plastic surgeons Tobias Hirsch and Maximilian Kueckelhaus to graft onto Hassans raw, bedridden body, which they did over the course of that October, November, and the following January.

It worked better than the boys doctors could have imagined. In 2017, de Luca, Hirsch, Kueckelhaus, and their colleagues reported that Hassan was doing well, living like a normal boy in his lab-grown skin. At the time though, there was still a big question on all their minds: How long would it last? Would the transgenic stem cells keep replenishing the skin or would they sputter out? Or worse could they trigger a cascade of cancer-causing reactions?

advertisement

Today, the same team is out with an update. Five years and five months after the initial intervention, Hassan is still, for the most part, thriving in fully functional skin that has grown with the now-teenager. He is attending school, and playing sports with his friends and siblings, though he avoids swimming due to blistering in the areas that werent replaced by the lab-grown skin. One of his favorite activities is a pedal-powered go kart. There are no signs his modified stem cells have lost their steam, and no traces of tumors to be found.

The encouraging follow-up data has been instrumental in moving forward a larger clinical trial of the approach, offering hope to the 500,000 epidermolysis bullosa patients worldwide currently living without treatment options.

We were astonished by the speedy recovery, Kueckelhaus, now at University Hospital Muenster, told STAT via email. But experience from skin transplantation in other settings made him and his colleagues wary of the grafts failing as the months and years wore on. Thankfully, wrote Kueckelhaus, those fears never materialized. We are very happy to be able to prove that none of these complications appeared and the genetically modified skin remains 100% stable. The chances are good that he will be able to live a relatively normal life.

Over the last five years, Hassans team of doctors and researchers has put his new skin through a battery of tests checking it for sensitivity to hot and cold, water retention, pigmentation and hemoglobin levels, and if it had developed all the structures youd expect healthy skin to have, including sweat glands and hair follicles. Across the board, the engineered skin appeared normal, without the need for moisturizers or medical ointments. The only flaw they found was that Hassans skin wasnt as sensitive to fine touch, especially in his lower right leg. This mild neuropathy they attributed not to the graft itself, but to how that limb was prepared doctors used a more aggressive technique that might have damaged the nerves there.

Related:

The team also used molecular techniques to trace the cells theyd grown in the lab as they divided and expanded over Hassans body. They found that all the different kinds of cells composing the boys new skin were being generated by a small pool of self-renewing stem cells called holoclone-forming cells, carrying the Italian teams genetic correction.

This was quite an insight into the biology of the epidermis, said de Luca. Its an insight he expects will have huge consequences for any efforts to advance similar gene therapies for treating other diseases affecting the skin. You have to have the holoclone-forming cells in your culture if you want to have long-lasting epidermis, he said.

The approach pioneered by de Lucas team will soon be headed for its biggest clinical test yet, after nearly a decade of fits and starts. They expect to begin recruiting for a multi-center Phase 2/3 trial sometime next year.

De Luca first successfully treated a junctional EB patient in 2005. But then a change to European Union laws governing cell and gene therapies forced his team to stop work while they found ways to comply with the new rules. It took years of paperwork, building a manufacturing facility, and spinning out a small biotech company called Holostem to be ready to begin clinical research again. Hassan came along right as they were gearing up for a Phase 1 trial, but data from the boys case, which was granted approval under a compassionate use provision, convinced regulators that the cell grafts could move to larger, more pivotal trials, according to de Luca.

We didnt cure the disease, he told STAT. But the skin has been restored, basically permanently. We did not observe a single blister in five years. The wound healing is normal, the skin is robust. From this point of view, the quality of life is not even comparable to what it was before.

Science Writer

Megan Molteni is a science writer for STAT, covering genomic medicine, neuroscience, and reproductive tech.

This name will appear with your comment

Read more here:
Syrian refugee is thriving five years after last-gasp gene therapy - STAT - STAT

Global Stem Cell Partnering Terms and Agreements 2021 Report – Featuring Regenetech, Stempeutics and Arthrex Among Others – ResearchAndMarkets.com -…

Country

United States of America US Virgin Islands United States Minor Outlying Islands Canada Mexico, United Mexican States Bahamas, Commonwealth of the Cuba, Republic of Dominican Republic Haiti, Republic of Jamaica Afghanistan Albania, People's Socialist Republic of Algeria, People's Democratic Republic of American Samoa Andorra, Principality of Angola, Republic of Anguilla Antarctica (the territory South of 60 deg S) Antigua and Barbuda Argentina, Argentine Republic Armenia Aruba Australia, Commonwealth of Austria, Republic of Azerbaijan, Republic of Bahrain, Kingdom of Bangladesh, People's Republic of Barbados Belarus Belgium, Kingdom of Belize Benin, People's Republic of Bermuda Bhutan, Kingdom of Bolivia, Republic of Bosnia and Herzegovina Botswana, Republic of Bouvet Island (Bouvetoya) Brazil, Federative Republic of British Indian Ocean Territory (Chagos Archipelago) British Virgin Islands Brunei Darussalam Bulgaria, People's Republic of Burkina Faso Burundi, Republic of Cambodia, Kingdom of Cameroon, United Republic of Cape Verde, Republic of Cayman Islands Central African Republic Chad, Republic of Chile, Republic of China, People's Republic of Christmas Island Cocos (Keeling) Islands Colombia, Republic of Comoros, Union of the Congo, Democratic Republic of Congo, People's Republic of Cook Islands Costa Rica, Republic of Cote D'Ivoire, Ivory Coast, Republic of the Cyprus, Republic of Czech Republic Denmark, Kingdom of Djibouti, Republic of Dominica, Commonwealth of Ecuador, Republic of Egypt, Arab Republic of El Salvador, Republic of Equatorial Guinea, Republic of Eritrea Estonia Ethiopia Faeroe Islands Falkland Islands (Malvinas) Fiji, Republic of the Fiji Islands Finland, Republic of France, French Republic French Guiana French Polynesia French Southern Territories Gabon, Gabonese Republic Gambia, Republic of the Georgia Germany Ghana, Republic of Gibraltar Greece, Hellenic Republic Greenland Grenada Guadaloupe Guam Guatemala, Republic of Guinea, Revolutionary People's Rep'c of Guinea-Bissau, Republic of Guyana, Republic of Heard and McDonald Islands Holy See (Vatican City State) Honduras, Republic of Hong Kong, Special Administrative Region of China Hrvatska (Croatia) Hungary, Hungarian People's Republic Iceland, Republic of India, Republic of Indonesia, Republic of Iran, Islamic Republic of Iraq, Republic of Ireland Israel, State of Italy, Italian Republic Japan Jordan, Hashemite Kingdom of Kazakhstan, Republic of Kenya, Republic of Kiribati, Republic of Korea, Democratic People's Republic of Korea, Republic of Kuwait, State of Kyrgyz Republic Lao People's Democratic Republic Latvia Lebanon, Lebanese Republic Lesotho, Kingdom of Liberia, Republic of Libyan Arab Jamahiriya Liechtenstein, Principality of Lithuania Luxembourg, Grand Duchy of Macao, Special Administrative Region of China Macedonia, the former Yugoslav Republic of Madagascar, Republic of Malawi, Republic of Malaysia Maldives, Republic of Mali, Republic of Malta, Republic of Marshall Islands Martinique Mauritania, Islamic Republic of Mauritius Mayotte Micronesia, Federated States of Moldova, Republic of Monaco, Principality of Mongolia, Mongolian People's Republic Montserrat Morocco, Kingdom of Mozambique, People's Republic of Myanmar Namibia Nauru, Republic of Nepal, Kingdom of Netherlands Antilles Netherlands, Kingdom of the New Caledonia New Zealand Nicaragua, Republic of Niger, Republic of the Nigeria, Federal Republic of Niue, Republic of Norfolk Island Northern Mariana Islands Norway, Kingdom of Oman, Sultanate of Pakistan, Islamic Republic of Palau Palestinian Territory, Occupied Panama, Republic of Papua New Guinea Paraguay, Republic of Peru, Republic of Philippines, Republic of the Pitcairn Island Poland, Polish People's Republic Portugal, Portuguese Republic Puerto Rico Qatar, State of Reunion Romania, Socialist Republic of Russian Federation Rwanda, Rwandese Republic Samoa, Independent State of San Marino, Republic of Sao Tome and Principe, Democratic Republic of Saudi Arabia, Kingdom of Senegal, Republic of Serbia and Montenegro Seychelles, Republic of Sierra Leone, Republic of Singapore, Republic of Slovakia (Slovak Republic) Slovenia Solomon Islands Somalia, Somali Republic South Africa, Republic of South Georgia and the South Sandwich Islands Spain, Spanish State Sri Lanka, Democratic Socialist Republic of St. Helena St. Kitts and Nevis St. Lucia St. Pierre and Miquelon St. Vincent and the Grenadines Sudan, Democratic Republic of the Suriname, Republic of Svalbard & Jan Mayen Islands Swaziland, Kingdom of Sweden, Kingdom of Switzerland, Swiss Confederation Syrian Arab Republic Taiwan, Province of China Tajikistan Tanzania, United Republic of Thailand, Kingdom of Timor-Leste, Democratic Republic of Togo, Togolese Republic Tokelau (Tokelau Islands) Tonga, Kingdom of Trinidad and Tobago, Republic of Tunisia, Republic of Turkey, Republic of Turkmenistan Turks and Caicos Islands Tuvalu Uganda, Republic of Ukraine United Arab Emirates United Kingdom of Great Britain & N. Ireland Uruguay, Eastern Republic of Uzbekistan Vanuatu Venezuela, Bolivarian Republic of Viet Nam, Socialist Republic of Wallis and Futuna Islands Western Sahara Yemen Zambia, Republic of Zimbabwe

Go here to see the original:
Global Stem Cell Partnering Terms and Agreements 2021 Report - Featuring Regenetech, Stempeutics and Arthrex Among Others - ResearchAndMarkets.com -...

Lab-grown embryos prompt a question: Are they getting too real? – STAT – STAT

The stem cells were no more than a week old when scientists moved them from their slick-walled plastic wells into ones lined with a thin layer of human endometrial tissue. But in that time, the cells had multiplied and transformed, organizing themselves into semi-hollow spheres. Per the instructions of the chemical cocktail in which theyd been steeping, they were trying to turn into embryos.

Video cameras captured what happened next: The balls of cells rotated until they were cavity-side-up, before finally touching down and grabbing onto the endometrial layer, a cellular proxy for a human uterus. Days later, when the scientists dipped paper test strips into the wells, pink lines appeared. Their Petri dishes were pregnant.

These experiments clearly point out the fact that we are able to model in the dish the first touch between the embryo and the mother, stem cell biologist Nicolas Rivron told reporters at a press conference.

advertisement

On Thursday, Rivron and his colleagues at the Institute of Molecular Biotechnology of the Austrian Academy of Sciences in Vienna reported in Nature that theyve learned to efficiently manufacture realistic models of human embryos from stem cells. These so-called blastoids arent the first successful attempt to recapitulate the developmental stage that embryos reach between four and seven days post-fertilization when theyre a blastocyst made up of about a hundred cells and ready to implant into the walls of the uterus but they appear to be the most advanced yet.

These synthetic embryos were made by mixing induced pluripotent stem cells with a brew of biochemical signals capable of coaxing them into forming spherical structures that include the beginnings of three distinct cell lineages outer layers representing the future placenta and amniotic sac, and an inner clump of cells with the potential to develop into a fetus.

advertisement

This is a very, very close model of a real, complete human embryo, said Insoo Hyun, director of research ethics at the Harvard Medical School Center for Bioethics, who was not involved in the study. Its probably the closest Ive seen.

The field of synthetic embryology has exploded in recent years. A parade of increasingly lifelike models that mimic portions of an embryos journey to personhood promise to shed light on critical moments of human development while providing a more flexible and ethical alternative to the study of human embryos, which has been historically limited by regulations and the willingness of IVF donors.

As the science of synthetic embryology gets more sophisticated, the models become more useful. But each advance raises a new round of ethical questions about where embryo models end and embryos begin. If it divides, organizes, and develops like an embryo, does it matter how it was made? Should an embryo derived from stem cells get the same legal and ethical rights as one produced when sperm met egg?

At some point we have to ask, when does an embryo model become so good that it functionally becomes an embryo? said Hyun. And for me, that question starts to get raised here. Its not that the latest work on blastoids was unethical, he clarified. On the contrary, it met all the guidelines issued by the International Society for Stem Cell Research (ISSCR), which Hyun helped write. The latest version, issued in May, prohibits scientists from transferring blastoids, which contain all the cell types necessary for development, into a human or animal uterus. It was a really well-done paper, I thought it was kind of stunning actually, said Hyun. It just opens up these other questions.

Related:

Already this year, five other groups around the world have independently reported methods for making blastoids, with varying degrees of efficiency and complexity. Two teams one at Monash University in Australia, one from the University of Texas Southwestern Medical Center in Dallas and Kunming Medical University in China published their results in Nature in March. Both teams also showed that their artificial structures formed similarly to real blastocysts. But both reported that only about 10% of the reprogrammed cells made the transition, and some of the structures contained cells not typically found in human blastocysts. Two other teams, one based in China and one based in the U.S. and the U.K., showed similar results while working with extended pluripotent stem cells. Another group, from the U.K., reported in Cell Stem Cell in June achieving much higher efficiencies between 30% and 80% of their stem cells expanded into blastoids. The Austrian groups blastoids were even more efficient, forming more than 70% of the time.

Its been a big year for blastoids, said Jianping Fu, a bioengineer at the University of Michigan whose lab created some of the earliest human embryo models from stem cells in 2017.

In 2018, Fu and Rivron joined Hyun and several others in writing an editorial urging lawmakers to ban the use of stem-cell based synthetic embryos for reproductive purposes while preserving their use for some types of research. They encouraged regulators to treat embryo models in the same way many nations dealt with cloning in the late 1990s and early 2000s. We think that the intention of the research should be considered the key ethical criterion by regulators, rather than surrogate measures of the equivalence between the human embryo and a model, they wrote.

Hyun said he still stands by those recommendations, to a point, even if it makes the slippery-slope crowd nervous. The further along you get in modeling pregnancy, the harder it is to justify those experiments on the grounds that theres no other way to answer your research question, said Hyun. Scientists have been able to glean insights into the earliest stages of development by studying human embryos donated by families whove undergone IVF. Tissue from aborted fetuses has provided clues about later stages of pregnancy. But from the time an embryo implants until the time a person realizes theyre pregnant, scientists have virtually no way of knowing whats going on.

Trending Now:

Its a total black box, said Hyun. But it maxes out at about 28 days. And what most people dont realize is that means theres a natural limitation on how long you could justify an experiment with synthetic embryos. Once you traverse the black box of development, theres no need to keep going in the dish.

Although its not required by law or the latest ISSCR guidelines, which relaxed the long-held 14-day rule barring research on embryos older than two weeks, the Austrian researchers did not allow their artificial embryos to develop past 13 days. But Rivron said he does not expect any of the blastoids to have the ability to develop into a complete embryo, even if allowed the chance.

A few years ago, his team successfully grew blastocysts in the lab from mouse stem cells. Ever since, theyve been implanting the blastoids into the uteruses of living mice and crossing their fingers. But theyve never successfully made any mice pups. Rivron said hed expect the same thing for their human blastoids if they were implanted into a functioning uterus (an experiment the ISSCRs guidelines, as well as laws in a handful of countries, expressly forbid). After implantation on the uterus-in-a-dish, the blastoids didnt grow or organize as well as what youd expect from real embryos in a real womb, said Rivron. These are very nice models, but we are far from any potential of using them for reproduction.

So how does he expect scientists might use them instead? A logical application would be to use them for drug discovery and screening a process that would require large numbers of these embry(ish)os. Now that we have formed a reliable embryo model, we can uniquely understand the molecules at play, and I believe that these molecules will actually become tomorrows medicines to enhance fertility or to be used as contraceptives, said Rivron. His group is already working with collaborators to test an FDA-approved drug that prevented the innermost cells of the blastoid from forming. Because those cells instruct the outer cells to become sticky, disrupting them could offer a hormone-free way to prevent embryos from implanting.

Other as-yet-discovered drugs could possibly enhance the implantation process, thereby improving the odds of getting pregnant. Compared to creating a fully competent synthetic embryo, using existing models to find and develop drugs is achievable on a relatively short timescale, said Rivron. This is not something that requires 10 years.

Other scientists have other ideas. Fu said an obvious immediate application would be to use large numbers of blastoids to systematically figure out better recipes for the medium that IVF clinics use to culture embryos prior to implantation. There are a lot of unknowns in how culture medium conditions affect the growth and development of human embryos, including successful implantation, said Fu. Those are questions that can better be answered now.

To Martin Pera, a stem cell researcher at the Jackson Laboratory, an even more powerful application would be to use these models to better understand how organisms precisely alter the expression of genes in different types of cells during early development. Its a very dynamic time, epigenetically, said Pera.

Since the 1990s, some scientists have argued for the fetal origins of adult disease; that the intrauterine environment, especially during times of bodily stress, may predispose a developing fetus to worse health outcomes later in life. We need models to replicate that, and this is an important start, Pera said.

Science Writer

Megan Molteni is a science writer for STAT, covering genomic medicine, neuroscience, and reproductive tech.

This name will appear with your comment

See the rest here:
Lab-grown embryos prompt a question: Are they getting too real? - STAT - STAT

Acrivon Therapeutics Announces its Scientific Advisory Board with Renowned Oncology Thought Leaders – The Bakersfield Californian

WATERTOWN, Mass., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc., a clinical-stage oncology therapeutics company with proprietary, proteomics-based technologies driving a new era of precision-based medicine, today announced the establishment of its scientific advisory board.

We are delighted to have these distinguished thought leaders in oncology research and development join our scientific advisory board, said Peter Blume-Jensen, M.D., Ph.D., chief executive officer and founder of Acrivon. Combined, they represent expertise across Acrivons key pillars of excellence including phospho-proteomics, predictive protein biomarkers, and oncology precision medicine. The caliber of this group, in addition to the high-quality investors who participated in our recent oversubscribed $100 million Series B financing, is a testament to the promise of our unique precision medicine platform.

George Demetri, M.D., professor at Harvard Medical School, co-director of the Ludwig Center, and senior vice president at the Dana-Farber Cancer Institute, added, I am very enthusiastic to help advance the potential benefit to patients from Acrivons pioneering proteomics-based precision medicine platform. The future of precision medicine lies in the ability to identify the right patients with complex cancers who can derive the maximal benefit from specific targeted therapies and rational combinations. Acrivons platform enables a unique approach to patient selection with the promise to be broadly applicable beyond the limitations of current tumor genome tests. We hope this will allow identification of direct mechanistic matching between the drug action with the primary drivers of malignancyin an individual patients tumor to predict treatment benefit with far less empiricism than current standards of care.

Scientific Advisory Board Members George Demetri, M.D., F.A.C.P., F.A.S.C.O., F.A.A.C.R. Dr. Demetri is co-director of the Ludwig Center at Harvard and professor of Medicine at Harvard Medical School and serves as senior vice president for experimental therapeutics at the Dana-Farber Cancer Institute (DFCI). Dr. Demetri was instrumental in the development of Gleevec (imatinib) as the first effective therapy for gastrointestinal stromal tumor (GIST) as a mutationally-driven solid tumor. His collaborative research efforts have contributed to worldwide regulatory approval of several other therapies, including sunitinib and regorafenib for GIST, as well as pazopanib, trabectedin, eribulin, and tazemetostat for other sarcomas. He is a member of the board of directors for Blueprint Medicines.

Dr. Demetri received his A.B. in Biochemistry at Harvard College and M.D. from Stanford Medical School. He completed his residency and chief residency at the University of Washington Hospitals in Seattle and his medical oncology fellowship at DFCI and Harvard Medical School. Dr. Demetri was the 2020 recipient of the David A. Karnofsky Memorial Award from the American Society of Clinical Oncology (ASCO).

Robert (Bob) Abraham, Ph.D. Dr. Abraham is executive vice president and head of cancer biology at Odyssey Therapeutics. Before that, he was most recently chief scientific officer at Vividion Therapeutics. Prior to Vividion, he was the senior vice president and world-wide head of the oncology R&D group at Pfizer. From 2005-2009, he was the head of oncology discovery research at Wyeth. During his tenure at Wyeth and Pfizer, Dr. Abraham contributed to the development of eight FDA-approved cancer drugs. Prior to joining industry, Dr. Abraham was a professor at the Sanford-Burnham-Prebys Medical Discovery Institute (SBPMDI) in La Jolla, CA, where he served as the director of the NCI-designated SBPMDI Cancer Research Center. Prior to SBPDMI, he was endowed chair in the Department of Pharmacology and Cancer Biology at the Duke University Medical Center. Prior to Duke University, Dr. Abraham held dual professorships in the departments of Immunology and Pharmacology at the Mayo Clinic in Rochester, MN. He maintains adjunct professor appointments at U.C. San Diego (Department of Pharmacology), and at the Sanford Burnham Prebys Institute.

Dr. Abraham began his career as an academic investigator, with enduring interests in cancer biology and immunology. His major research interests included characterization and functional analysis of the mammalian Target of Rapamycin (mTOR) signaling pathway, cancer metabolism, cellular signaling and DNA damage responses. Dr. Abraham has authored over 225 scientific publications, and his published work has been cited over 48,000 times. Dr. Abraham received his B.S. in Biology from Bucknell University and his Ph.D. in Pharmacology at the University of Pittsburgh, and he completed his postdoctoral training in Pharmacology and Immunology at the Mayo Clinic.

Timothy A. Yap, M.B.B.S., Ph.D., F.R.C.P. Dr. Yap is an associate professor in the departments for Investigational Cancer Therapeutics and Thoracic/Head and Neck Medical Oncology at the MD Anderson Cancer Center. He is also the medical director of the Institute for Applied Cancer Science, a drug discovery biopharmaceutical unit where drug discovery and clinical translation are seamlessly integrated. He is also an associate director of translational research at the Institute for Personalized Cancer Therapy, an integrated research and clinical trials program. Previously, Dr. Yap was a consultant medical oncologist at The Royal Marsden Hospital in London, UK and National Institute for Health Research BRC clinician scientist at The Institute of Cancer Research, London, UK.

Dr. Yaps primary research focuses on development of targeted agents and their acceleration through biomarker-driven clinical trials. His main interests include targeting of the DNA damage response as well as the development of novel immunotherapeutics, and past and currenthe is and/or has been a principal investigator for multiple clinical trials evaluating novel strategies for targeting the DNA damage response in cancer. Dr. Yap obtained his B.Sc. degree in Immunology and Infectious Diseases at Imperial College London, UK, and subsequently went on to attain his medical degree from Imperial College London, UK. He has a Ph.D. in Molecular Pharmacology from the Division of Cancer Therapeutics at the Institute of Cancer Research, London, UK.

David Berman, M.D., Ph.D. Dr. Berman is a professor and chair of the department of Pathology and Molecular Medicine at Queen's University in Kingston, Ontario. He is board certified in Anatomic Pathology and practices urologic surgical pathology at Kingston Health Sciences Centre while also running a biomarker discovery laboratory focused on urologic cancers. Dr. Berman earned his M.D. and Ph.D. (Genetics and Development) degrees from the University of Texas, Southwestern Medical Center. He completed residency training and a postdoctoral research fellowship at Johns Hopkins where he established his independent research laboratory, which moved to Canada in 2012. The Berman laboratory focuses on basic, translational, and clinical aspects of prostate and bladder cancer. His research has helped identify bladder cancer stem cells and druggable targets in embryonic signaling pathways, and it has helped improve surgical pathology practice.

Dr. Berman was director of the Queens Cancer Research Institute from 2015-2021 and has served on research advisory committees for the Canadian Cancer Society (ACOR), the Canadian Cancer Trials Group, and Bladder Cancer Canada. He currently leads a translational research effort for the Canadian Bladder Cancer Research Network.

Jesper Olsen, Ph.D. Dr. Olsen is an academic co-founder and head of phosphoproteomics at Acrivon Therapeutics, Inc. He is a professor in quantitative proteomics at the University of Copenhagen and vice director of the Novo Nordisk Foundation Center for Protein Research. Dr. Olsen is a pioneer in mass spectrometry based phosphoproteomics and its applications to decipher cell-signaling networks at a systems-wide scale, and his research interest is developing and applying phosphoproteomics technologies for comprehensive kinase drug profilings with clinical actionability. Dr. Olsen is the most cited phosphoproteomics expert world-wide and among top 0.1% in protein sciences.

Dr. Olsen received his M.Sc. in Analytical Chemistry at the University of Southern Denmark and his Ph.D. in Biochemistry and Molecular Biology at the same place under the supervision of Prof. Matthias Mann. Dr. Olsen completed his post-doctoral training in proteomics and cell signaling at the Max Planck Institute for Biochemistry in Munich. He is based in Copenhagen since 2009, where he joined the newly established Center for Protein Research, initially as group leader and since 2014 as vice director.

About Acrivon Acrivon is a clinical stage oncology company leveraging its unique, proprietary phosphoproteomics technology called Acrivon Precision Predictive Proteomics, or AP3, in development of its pipeline of oncology drugs. The AP3 platform enables the creation of drug-specific proprietary OncoSignature companion diagnostics that can be used to identify patients most likely to benefit from Acrivons medicines. Through its highly specific patient selection, the company seeks to accelerate clinical development and increase the probability of successful treatment outcome for patients. The companys pipeline includes the clinically advanced lead program, ACR-368 (also known as prexasertib), a targeted oncology asset in-licensed from Lilly which has demonstrated evidence of durable responses, in solid cancers in Phase 2 trials. Acrivon is also developing additional pipeline programs targeting critical nodes in DNA Damage Response (DDR) and cell cycle regulation. Please visit the companys website at https://acrivon.com for more information.

Acrivon Contacts: Alexandra Santos asantos@wheelhouselsa.com

Aljanae Reynolds areynolds@wheelhouselsa.com

Read the rest here:
Acrivon Therapeutics Announces its Scientific Advisory Board with Renowned Oncology Thought Leaders - The Bakersfield Californian

Be The Match BioTherapies and Vineti collaborate to develop innovative, integrated supply chain management solutions for cell and gene therapies -…

MINNEAPOLIS and SAN FRANCISCO, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Be The Match BioTherapies, an organization offering solutions for companies developing and commercializing cell and gene therapies (CGTs), and Vineti, the provider of the leading digital enterprise platform for cell and gene therapy supply chains, today announced a collaboration to develop joint solutions that simplify and scale supply chain management of cell and gene therapies.

The non-exclusive collaboration will bring together industry leaders in workflow and logistics solutions -- Be The Match BioTherapies cellular therapy supply chain management services and Vinetis Personalized Therapy Management (PTM) platform. The collaboration will enable the Be The Match BioTherapies Cell Therapy Supply Chain Managers and Logistics Coordinators to utilize the PTM platform on behalf of shared biopharmaceutical clients with greater efficiency and simplicity.

The organizations leverage complementary strengths in starting material collection, cell therapy supply chain and managed logistics, Chain of Identity (COI) and Chain of Custody (COC), and enterprise-grade digital solutions for end-to-end value chain management. The collaboration will provide unique integrated solutions for these mission-critical components of CGT operations, and will simplify workflows, speed time to treatment, and provide the flexibility that CGT development requires.

This is a message to the industry that both parties are committed to improving our clients experience, and to improving outcomes for patients by building a combined solution that eliminates unnecessary complexity, said Amy Ronneberg, CEO of the National Marrow Donor Program (NMDP)/Be The Match and Be The Match BioTherapies.

By combining each teams core expertise, the organizations aim to create innovative solutions that blend Be The Match BioTherapies best in class cell therapy supply chain services with Vinetis proven expertise in advanced therapy management and enterprise grade digital technology to deliver next-generation therapy management, automated traceability, and digitized compliance for CGTs.

Were very honored to partner with Be The Match BioTherapies, said Amy DuRoss, CEO and Co-founder of Vineti. Both organizations share a focus on driving transformative outcomes for patients that wouldnt be possible without cell and gene therapies. Well be able to offer a solution that reduces timelines to the clinic, while allowing CGT developers to simplify and scale operations with best-in-case expertise, services, and digital tools.

The Be The Match BioTherapies-Vineti solution will be available from both organizations Business Development teams. This news follows the recent Be The Match BioTherapies webinar on scalable and efficient cell collection networks as well as Vinetis recent partnership announcement with Autolomous.

About Be The Match BioTherapies

Be The Match BioTherapiesis the only cell and gene therapy solutions provider with customizable services to support the end-to-end cell therapy supply chain. Backed by the industry-leading experience of theNational Marrow Donor Program/Be The Match, and a research partnership with theCIBMTR(Center for International Blood and Marrow Transplant Research), the organization designs solutions that advance the development of cell and gene therapies across the globe.

Be The Match BioTherapies is dedicated to accelerating patient access to life-saving cell and gene therapies by providing high-quality cellular source material from theBe The Match Registry, the worlds most diverse registry of more than 22 million potential blood stem cell donors. Through established relationships with apheresis, marrow collection, and transplant centers worldwide, the organization develops, onboards, trains, and manages expansive collection networks to advance cell therapies. Be The Match BioTherapies uses a proven infrastructure consisting of regulatory compliance and managed logistics experts and cell therapy supply chain case managers to transport and deliver regulatory-compliant life-saving therapies across the globe successfully. Through the CIBMTR, Be The Match BioTherapies extends services beyond the cell therapy supply chain to include long-term follow-up tracking for the first two FDA-approved CAR-T therapies.

For more information, visitwww.BeTheMatchBioTherapies.comor follow Be The Match BioTherapies onLinkedInor Twitter.

About Vineti

Vineti offers the first commercial, configurable cloud-based platform to expand patient access to life-saving cell and gene therapies. Vineti was co-founded by GE and the Mayo Clinic to solve the key challenges that patients, medical providers, biopharmaceutical companies, and regulators face in the delivery and commercialization of individualized therapies. Now a fully independent company, Vineti offers a digital platform of record to integrate logistics, supply chain management, manufacturing, and clinical data for personalized therapies. The Vineti Personalized Therapy Management(PTM) platform aligns and orchestrates the advanced therapy process and improves product performance overall, supporting the full continuum of patient-specific therapies, including personalized cancer vaccines and autologous and allogeneic cell and gene therapies. Vineti is currently serving patients, healthcare providers, and researchers in hundreds of leading medical centers and manufacturing centers world-wide on behalf of a growing number of biopharmaceutical partners. The World Economic Forum has honored Vineti as a World Economic Forum Technology Pioneer. Vineti is headquartered in San Francisco, California, with teams based in the Washington, D.C. area and Yerevan, Armenia. For more information, please visithttp://vineti.com.

Contact Information:

Bonnie Quintanilla, Clarity Quest (for Be The Match BioTherapies) bonnie@clarityqst.com

Dan Budwick, 1AB Media (for Vineti) dan@1abmedia.com

Excerpt from:
Be The Match BioTherapies and Vineti collaborate to develop innovative, integrated supply chain management solutions for cell and gene therapies -...

Surgical Sutures Market to Grow by 5.6% as Application Increases in Knotless and Electronic Products Manufacturing – BioSpace

Surgical Sutures Market Value to Reach US$ 6.5 Bn as Governments Eliminate Trade Duties on Medical Devices

Fact.MR combines trend analysis and quantitative forecasting to provide readers with the latest insight of the surgical sutures market. The study contains distinctive information through exhaustive primary and secondary research methodologies. It also includes detailed information about various segments in terms of product type, raw material, source, application, and end-user across seven major regions.

Fact.MR A Market Research and Competitive Intelligence Provider: The global surgical sutures market is expected to reach US$ 6.5 Bn, exhibiting growth at a CAGR of 5.6% during 2021 to 2031, estimates Fact.MR. Rising number of trauma patients are expected to drive the growth in the surgical sutures market.

Surgical sutures have gained immense popularity across the globe owing to ongoing technological advancement in this field. Governments of various countries are also supporting the usage of these products for improving their healthcare facilities.

Additionally, compared to the conventional non-absorbable sutures, the new absorbable ones are the most preferred sutures among surgeons across the globe due to their high Average Selling Price (ASP).

Further, several manufacturers are investing extensively to develop novel electronic, bioactive, antimicrobial, and knotless surgical sutures for the healthcare sector. These new sutures are beneficial in detecting infections or leakages in the wound.

Also, to enable efficient drug delivery to the surgical site, some of the key players have come up with stem cell-seeded and drug-eluting sutures. These factors are anticipated to bolster the surgical sutures market growth in the forecast period.

With governments eliminating restrictions, trade duties, and customs on medical devices by launching new agreements, sales of surgical sutures are expected to witness an uptick through 2021. The Trans-Pacific Partnership (TPP) and the North American Free Trade Agreement (NAFTA) are the two significant examples of such agreements. This has helped the market to generate nearly US$ 20.5 trillion of revenue and the trend is likely to continue over the coming years, declares a Fact.MR analyst.

Request a report sample to gain comprehensive insights at

https://www.factmr.com/connectus/sample?flag=S&rep_id=4065

Key Takeaways:

Growth Drivers:

Restraints:

Request for customization at

https://www.factmr.com/connectus/sample?flag=RC&rep_id=4065

Competitive Landscape

Presence of numerous leading players in the surgical suture market has led to severe competition in the market. Some of these companies are adopting strategies, such as mergers & acquisitions, partnerships, and new product development to gain competitive edge.

Meanwhile, some of the players are teaming up with start-up companies to develop joint ventures to strengthen their positions in the market.

For instance,

Key Players in the Surgical Sutures Market Include:

More Valuable Insights on Surgical Sutures Market

Fact.MR provides an unbiased analysis of the surgical sutures market, presenting historical demand data (2016-2020) and forecast statistics for the period from 2021-2031. The study divulges compelling insights on the global surgical sutures market with a detailed segmentation on the basis of:

Product Type

Raw Material

Source

Application

End-user

Region

Key Questions Covered in Surgical Sutures Market Report

Explore Fact.MRs Coverage on the Healthcare Domain

Absorbable Surgical Sutures Market Report: Absorbable Surgical Sutures market analysis is done on the basis of product (Polyglycolic Acid sutures, Polyglactin 910, Catgut absorbable sutures, Poliglecaprone 25, Polydioxanonen absorbable surgical sutures)

Polyglyconate Sutures Market Analysis: Polyglyconate Sutures Market Analysis on the basis of Applications (Cardiovascular Surgeries, General Surgeries, Gynecological Surgeries & Orthopedic Surgeries). Rising number of surgeries and augmenting demand for advanced treatment procedures propel the market of polyglyconate sutures market in North America.

Laparoscopic Sutures Market Research: Laparoscopic Sutures Market analysis on the basis of Product type (Stitch Suturing Devices & Laparoscopy Suturing Needles). Laparoscopic needles are expected to hold a large revenue share in the laparoscopic sutures market.

About Fact.MR

Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. Spanning a wide range from automotive & industry 4.0 to healthcare, technology to even the most niche categories. 80% of Fortune 1000's trust us in critical decision making.

MarketNgage is powered by Fact.MR our Unified Intelligence Engine, a revolutionary Market Research Subscription platform with a flexible pricing to suit your needs.

You can access all our healthcare research reports by signing up with MarketNgagesMarket Research Subscriptionwith FREE credits. MarketNgage is powered by Fact.MR A Fully integrated research solution for seamless single-window access Widest coverage on emerging markets, nascent products, and disruptive technologies.

Contact:

Mahendra Singh US Sales Office 11140 Rockville Pike Suite 400 Rockville, MD 20852 United States Tel: +1 (628) 251-1583 E: sales@factmr.com

Source: Fact.MR

Read the original:
Surgical Sutures Market to Grow by 5.6% as Application Increases in Knotless and Electronic Products Manufacturing - BioSpace

Ncardia inks $60M funding deal to expand discovery and commercial production services for stem cells – FierceBiotech

Ncardia is the result of the 2017 merger of Pluriomics and Axiogenesis. (Getty/designer491)

Ncardia, a human-induced pluripotent stem cell developer,picked up $60 million via a strategic partnership with Kiniciti.

The Belgian iPSC contract research, development and manufacturing company is partnering with the U.S. investment firm to boost discovery, clinical and commercial production capabilities, the companiessaid Tuesday.

Ncardia manufactures iPSC derived cells and provides assay development, disease modeling and cell-based screening. The company is the result of a 2017 combination ofPluriomics and Axiogenesis. Within months of the merger,Ncardiasigned disease modeling licensing pacts with Roche and Evotec.

Now, through its Kiniciti deal, Ncardia can expand globally and invest in good manufacturing practice capabilities for cell therapies, the company said. Ncardia's discovery services will benefit from the financing, said Kiniciti CEO Geoff Glass in a statement.

RELATED:On back of Roche pact, newly formed Ncardia wins iPSC deal with Evotec

That includes building more human cellular models that can predict whether drugs are safe and effective earlier in the development stage, said Stefan Braam, Ph.D., CEO and co-founder of Ncardia, in a statement. The manufacturing technology will go toward iPSC-based allogenic platforms for immuno-oncology.

Kiniciti is a platform company from private equity firm Welsh, Carson, Anderson & Stowe that launched in February with$250 million to invest in non-therapeutic cell and gene therapy startups.Biospring Partners joinedas an investor earlier this month for an undisclosed amount.

See the article here:
Ncardia inks $60M funding deal to expand discovery and commercial production services for stem cells - FierceBiotech